论文部分内容阅读
目的 探讨洛伐他汀和氟伐他汀对急性冠脉综合征患者血清高敏C 反应蛋白 (hs CRP)及血脂水平的影响。方法 78例急性冠脉综合征患者随机单盲分为 3组 ,其中对照组 (A组 ) 18例 ;洛伐他汀组(B组 ) 30例 ,2 0mg/d ;氟伐他汀组 (C组 ) 30例 ,2 0mg/d ;随访 30天 ,检测患者治疗前后 30天血清的hs CRP浓度和血脂浓度变化。结果 治疗 30天后 ,B、C组能显著降低血总胆固醇 (TC)、甘油三酯 (TG)及低密度脂蛋白 (LDL)水平、升高血高密度脂蛋白 (HDL) ;两组间疗效无明显差异。B、C组能显著降低hs CRP的浓度 ,两组间疗效无明显差异。B、C组患者的血清hs CRP水平降低与血清TC、TG、LDL的水平降低、HDL的水平升高不相关。结论 洛伐他汀和氟伐他汀治疗急性冠脉综合征患者 30天就可明显改善血脂 ,降低hs CRP水平 ,并且具有抗炎症和稳定冠状动脉斑块的作用
Objective To investigate the effects of lovastatin and fluvastatin on serum high-sensitivity C-reactive protein (hs CRP) and serum lipids in patients with acute coronary syndrome. Methods A total of 78 patients with acute coronary syndrome were randomly divided into three groups randomly. The control group (A group), 18 cases, Lovastatin group (B group), 30 cases, 20 mg / d, fluvastatin group ) 30 cases, 20mg / d; 30 days follow-up, detection of serum hs CRP concentration and serum lipid concentrations 30 days before and after treatment. Results After treatment for 30 days, the levels of total cholesterol (TC), triglyceride (TG) and low density lipoprotein (LDL) and the level of serum high density lipoprotein (HDL) were significantly decreased in groups B and C; No significant difference. B, C group can significantly reduce the concentration of hs CRP, no significant difference between the two groups. The serum hs CRP levels in patients of group B and C were not correlated with the decrease of serum TC, TG and LDL levels and the increase of HDL levels. Conclusions Lovastatin and fluvastatin can significantly improve blood lipids, reduce the level of hs CRP, and have anti-inflammatory and stable coronary plaque in 30-day treatment of patients with acute coronary syndrome